logo  
Sign in or Register

Already a member?

Sign in

Or sign in with your account on:

Not a member yet?

Register
    

Retrophin Raises Offer to Acquire Transcept Pharmaceuticals to $4 Per Share

By  +Follow September 19, 2013 8:51AM
Share:
Tickers Mentioned:

Retrophin, Inc. (RTRX) is not giving up on its pursuit to acquire the shares of specialty drug maker Transcept Pharmaceuticals, Inc. (TSPT) that it does not already own.  Last week, Retrophin delivered a letter to the board of directors of Transcept offering to buy the remaining shares for $3.50 each in cash.  The offer was rejected. 

To defend itself from a hostile takeover, Transcept has adopted a shareholder rights plan, often called a “poison pill,” which keeps a shareholder from acquiring more than 4.99 percent of the company.

On Wednesday, Retrophin bumped the offer up to $4.00 per share, with Retrophin chief executive Martin Shkreli sending a letter to the board members of Transcept.

Transcept is focused on development of neuroscience drugs with its only FDA approval being the oral sleep aid Intermezzo (zolpidem tartrate).  Purdue Pharma holds commercialization and development right for Intermezzo in the U.S.  Royalty revenue for Transcept from Intermezzo in the first six months of 2013 was $1.0 million, up from $500,000 in the year prior period. 

Net loss for the six months ended June 30, 2013 was approximately $17.2 million, or $0.92 per share, versus a net loss of approximately $10.3 million, or $0.67 per share, for the six months of 2012.

Retrophin has four drugs in its pipeline with RE-021 the only one in the clinical stage, being researched in a mid-stage trial for Focal Segmental Glomerulosclerosis, a disease that can cause nephrotic syndrome in children and kidney failure in adults.  The company’s other compounds are targeting hard-to-treat diseases like Pantothenate Kinase-Associated Neurodegeneration (PKAN) and Duchenne Muscular Dystrophy.

In recent weeks, three major shareholders of Transcept have publicly stated their disapproval of Transcept’s current strategy.  Activist investor Peter Collery of SC Fundamental LLC, which owns a 6.7-percent stake in Transcept, sent a letter to Transcept chief executive, president and director Glenn Oclassen (read the SEC filing) saying that the company needs to use $60 million of its cash to conduct a share repurchase to build value, not pursue “simply wrongheaded,” (but unnamed) projects.

Collery didn’t hold back much in expressing his feelings toward Transept management.  Such as:

“I should note how troubled we are by your presumption that the company’s money is yours to do with as you see fit. You and your fellow directors have a fiduciary duty to company shareholders.”

And...

“I’d like, in closing, also to express my displeasure with the company’s recent grant of nearly 600,000 management stock options with a strike price of $2.93 per share. As described above, the company’s shares may have a current realizable value of $5 or so. Were Transcept to implement a buyback program, that value might rise to $6. Essentially no management skill would be required to realize these values. That the shares trade for less than $3 is a function of shareholders’ distrust of management. It is incredible that management should be granted undervalued stock options as a “reward” for having created that distrust and I would expect that an inquiry into the deliberations surrounding this recent option grant, and particularly, the suitability of the strike price would be quite interesting.”

Roumell Asset Management, LLC, the largest Transcept shareholder at 12.3 percent of the company, has also filed a 13D with the SEC criticizing the management and demanding a share buy-back plan, not an unidentified acquisition.

The new proposal by Retrophin offers to buy Transcept at a 20-percent premium to Tuesday’s closing price.  The price is still lower than the $6 mark that Collery believes can be attained by performing a share repurchase, but this is a little to-may-toes/to-ma-toes because a merged company could benefit similarly, so investors will have to see where the support falls with the new proposal.

“Our proposal represents an attractive premium to Transcept’s trading performance, and we believe that the proposal offers a compelling opportunity for Transcept’s stockholders, particularly in light of Transcept’s risky and controversial acquisition strategy,” stated Martin Shkreli, Chief Executive Officer of Retrophin. “We hope that Transcept’s Board of Directors will respect its stockholders’ wishes and quickly commence discussions with us regarding the proposed transaction.”

Retrophin wants a transaction to be entered into by the end of September.

Shares of TSPT are down about 18 percent in 2013 thanks to a run-up from lows of $2.52 late in August with the acquisition chatter.  At lows, the stock was off about 40 percent.  Shares rose by 8 percent in Wednesday trading to close at $3.59.  In extended trading, shares rose to $3.98.  Retrophin shares edged up about 1 percent on the day to $6.88.  Shares have more than doubled in 2013.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions.


Signup for our daily newsletter and get our best articles emailed right to you!

Results for rtrx
Stockaholics
24 Oct 14 13:53:11
Our Penny Stock Alerts Gained 371% In 2 weeks! Sign Up For Free Text Alerts For Our New Pick: http://t.co/dLDRavoCi4 $RTRX $CPST $TGTX
Roy Friedman
24 Oct 14 11:13:55
Class-action suit against $RTRX (probably 1st of several): http://t.co/fUsKTZpXPz
On Time Picks
24 Oct 14 11:13:38
DewDiligence: Class-action suit against $RTRX (probably the first of several):: DewDiligence http://t.co/7AdoOPfsxl
4-traders.com
24 Oct 14 11:00:06
Retrophin : Federman & Sherwood : Announces Filing of Securities Class Action Lawsuit Against Retrophin, Inc. http://t.co/iRLnPOUXwV $RTRX
Stock Relay
24 Oct 14 09:37:21
$EGLT Stock Message Board Click Here: http://t.co/RX20fJ5iIi Also See: $ESBF $PBSK $RTRX $GSM ~
Stockaholics
24 Oct 14 09:33:41
Our Penny Stock Alerts Gained 371% In 2 weeks! Sign Up For Free Text Alerts For Our New Pick: http://t.co/dLDRavoCi4 $RTRX $CPST $TGTX
Zachary Prensky
24 Oct 14 09:08:20
@Thug_BioAnalyst I hope the folks at $RTRX are pushing the sell button on a good portion of the $CLVLY stake
Colfax
24 Oct 14 07:43:13
RT @Thug_BioAnalyst: $RTRX still owns at least 2.9mm shares of $CLVLY n' $CUV.AX per filings. dey would have 2 days to file any changes ove…
Thug Biotech Analyst
24 Oct 14 07:42:08
$RTRX still owns at least 2.9mm shares of $CLVLY n' $CUV.AX per filings. dey would have 2 days to file any changes over 1% of voting right
Brad Loncar
24 Oct 14 07:26:50
@chasingthealpha At this early point, revenue is based on promises, which hasn't been $RTRX's strong point. I can see why buyers would wait.
Lombard Capital
24 Oct 14 07:20:50
@sharkbiotech who is pumping $BLUE now? $RTRX employees? Nice!! Pump it to $50.
Patrick
24 Oct 14 07:13:05
$RTRX should be up more
Edmund Sullivan
24 Oct 14 05:18:48
RT @bradloncar: Clinuvel Scenesse approved under exceptional circumstances. $RTRX
BioInvestor
24 Oct 14 04:34:04
Clinuvel scenesse approval should be good for $RTRX. Do they still own the stock? http://t.co/BElYAYUPrv
Colfax
24 Oct 14 04:16:35
RT @bradloncar: Clinuvel Scenesse approved under exceptional circumstances. $RTRX
Patrick
24 Oct 14 04:05:51
$CUV.AX RT @bradloncar: Clinuvel Scenesse approved under exceptional circumstances. $RTRX
Thug Biotech Analyst
24 Oct 14 04:05:08
RT @bradloncar: Clinuvel Scenesse approved under exceptional circumstances. $RTRX
Brad Loncar
24 Oct 14 04:02:12
Clinuvel Scenesse approved under exceptional circumstances. $RTRX
Penny Stock Secret
23 Oct 14 12:48:21
The Hottest Way to Make Millions From Stock Market.Click HERE http://t.co/AJZWTGD3tb .. $RTRX $CUBA $MKTX
Stockaholics
23 Oct 14 12:02:57
Our Penny Stock Alerts Gained 371% In 2 weeks! Sign Up For Free Text Alerts For Our New Pick: http://t.co/dLDRavoCi4 $RTRX $CPST $TGTX
Class Actions News
23 Oct 14 08:11:33
$RTRX shareholder sues re loss due to unauthorized stock grants. CEO fired. BOD member resigns. more here #corpgov http://t.co/pO0yrPlbTp
Stockaholics
23 Oct 14 01:06:53
Our Penny Stock Picks Gained 371% In 2 Weeks! Get Our Next Pick Early: http://t.co/z2noBUWrEP $RTRX $CPST $TGTX
wininstocks2014
23 Oct 14 00:19:57
RTRX 9.55 Stock Charts $RTRX Retrophin Inc. (NASDAQ) Last Updated: 10/23/2014 02:19:54 RTRX Stock Chart - 1 Mo http://t.co/eIoJwUIKwR
4-traders.com
22 Oct 14 20:05:03
Retrophin : Announces Divestment of Non-Core Assets to Turing Pharmaceuticals http://t.co/B65pUIx38D $RTRX
Pzaa...Guy
22 Oct 14 17:12:06
$RTRX - Harwood Feffer LLP Announces Investigation of Retrophin, Inc. http://t.co/Sny2AsRowW
NASDAQ
22 Oct 14 17:12:02
$RTRX - Harwood Feffer LLP Announces Investigation of Retrophin, Inc. http://t.co/KosaHlCYsU
Stockaholics
22 Oct 14 13:45:10
Our Penny Stock Picks Gained 371% In 2 Weeks! Get Our Next Pick Early: http://t.co/z2noBUWrEP $RTRX $CPST $TGTX
Pzaa...Guy
22 Oct 14 07:31:23
$RTRX - INVESTOR ALERT: Class Action Lawsuit Against Retrophin, Inc. Announced by Glancy Binkow & Goldberg LLP http://t.co/Ee6oEJYMg8
NASDAQ
22 Oct 14 07:31:16
$RTRX - INVESTOR ALERT: Class Action Lawsuit Against Retrophin, Inc. Announced by Glancy Binkow & Goldberg LLP http://t.co/TAgztzXbXq
Stockaholics
22 Oct 14 01:15:00
Our Penny Stock Picks Gained 371% In 2 Weeks! Get Our Next Pick Early: http://t.co/z2noBUWrEP $RTRX $CPST $TGTX
Stockaholics
21 Oct 14 21:22:32
Our Penny Stock Picks Gained 371% In 2 Weeks! Get Our Next Pick Early: http://t.co/z2noBUWrEP $RTRX $CPST $TGTX
Pzaa...Guy
21 Oct 14 15:06:05
$RTRX - INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 http://t.co/YXtBBhA3ol
NASDAQ
21 Oct 14 15:06:01
$RTRX - INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 http://t.co/yWj5Y24V8Y
DailyStockPicks
21 Oct 14 11:35:42
Earnings out for Owens Corning tomorrow. Is it due for a collapse? http://t.co/Est9NjxYUb $ENTA $RTRX $FITX $GILD $GPRO $IBIO $IBM $DGLY
Stockaholics
21 Oct 14 00:53:22
Our Penny Stock Picks Gained 371% In 2 Weeks! Get Our Next Pick Early: http://t.co/z2noBUWrEP $RTRX $CPST $TGTX
Stockaholics
20 Oct 14 20:30:07
Our Penny Stock Picks Gained 371% In 2 Weeks! Get Our Next Pick Early: http://t.co/z2noBUWrEP $RTRX $CPST $TGTX
Stockaholics
20 Oct 14 16:49:41
Our Penny Stock Picks Gained 371% In 2 Weeks! Get Our Next Pick Early: http://t.co/z2noBUWrEP $RTRX $CPST $TGTX
Stockaholics
20 Oct 14 12:14:22
After Massive Gains On Penny Stock Picks, another New Pick Is Coming! Check it out: http://t.co/YX0NLZhRQ5 $RTRX $CPST $TGTX
Bryan Campbell
20 Oct 14 09:09:44
RT @MKerryFuller: $RTRX when does @adamfeuerstein do his annual worst CEO list? I have a nomination for him.
mohamed
20 Oct 14 08:38:57
@MartinShkreli hello Martin, how can I access $RTRX conference call, I HEARD YOU WILL BE PARTICIPAING, CANT WAIT TO HEAR FROM YOU
Patrick
20 Oct 14 07:45:29
RT @vram2000: $RTRX My Q3 revenue estimate: $12-15MM. We should c Thiola sales. Q3 conf call should be interesting. Will they let @MartinSh…
Martin Shkreli
20 Oct 14 07:29:23
@ColfaxCapital @vram2000 will start commenting a bit on $RTRX soon. i think the stock is very cheap. not selling anytime soon unless i must
BioInvestor
20 Oct 14 07:09:50
$RTRX My Q3 revenue estimate: $12-15MM. We should c Thiola sales. Q3 conf call should be interesting. Will they let @MartinShkreli ask Q's?
Stockaholics
19 Oct 14 23:48:51
After Massive Gains On Penny Stock Picks, another New Pick Is Coming! Check it out: http://t.co/YX0NLZhRQ5 $RTRX $CPST $TGTX
Stockaholics
19 Oct 14 16:46:04
IBIO Closed Up 69.84% After Our Penny Stock Alert! New Picks Coming: http://t.co/OG2rloNNni $RTRX $CPST $TGTX
nixon786
19 Oct 14 11:52:52
@Thug_BioAnalyst Heard he left $RTRX
Stockaholics
18 Oct 14 14:00:57
IBIO Closed Up 69.84% After Our Penny Stock Alert! New Picks Coming: http://t.co/OG2rloNNni $RTRX $CPST $TGTX
Stockaholics
18 Oct 14 11:28:33
IBIO Closed Up 69.84% After Our Penny Stock Alert! New Picks Coming: http://t.co/OG2rloNNni $RTRX $CPST $TGTX
Stockaholics
18 Oct 14 03:18:14
IBIO Closed Up 69.84% After Our Penny Stock Alert! New Picks Coming: http://t.co/OG2rloNNni $RTRX $CPST $TGTX
Yu Zhu
17 Oct 14 15:50:34
RT @BentheFidler: East Coast Biotech Roundup: Raze, Retrophin, Alnylam, & More http://t.co/dxS7Ogeh78 $ALNY $RTRX $BLUE $EPZM $ZFGN $SAGE …
				
				
By  +Follow September 19, 2013 8:51AM
Share:

Comments

 

blog comments powered by Disqus

About us

Equities.com is the most advanced interactive online social ecosystem for the financial industry, serving as a resource center and next-generation communication platform that connects self-directed investors with public issuers, market experts, and professional service providers and vendors. Registered members can leverage our exclusive proprietary research tools such as the Small-Cap Stars, which outperformed 90% of all small-cap mutual funds, and robust do-it-yourself E.V.A. research reports. The Equities.com Issuer Dashboard is the ideal tool to communicate and manage investor awareness campaigns to the investment community, as well as to access valuable resources to help your company grow.

Market Data powered by QuoteMedia.
Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. Terms of Use.